The expression and pathophysiological role of osteopontin in Graves' disease

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 11, 2011, Pages

  Xu, Lingyan ^a   Ma, Xinran ^a   Wang, Yanyan ^a,b   Li, Xiaoli ^a,b   Qi, Yicheng ^a,b   Cui, Bin ^a   Li, Xiaoying ^a,b   Ning, Guang ^a,b   Wang, Shu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA8BETA1 INTEGRIN; ALPHAVBETA1 INTEGRIN; ALPHAVBETA5 INTEGRIN; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; GAMMA INTERFERON; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIOTHYRONINE; MONOCLONAL ANTIBODY; OSTEOPONTIN; OSTEOPONTIN RECEPTOR; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VITRONECTIN RECEPTOR;

ADULT; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GRAVES DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; FEMALE; GRAVES DISEASE; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; MIDDLE AGED; OSTEOPONTIN;

EID: 80655147235     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1339     Document Type: Article

References (15)

1. Prabhakar BS, Bahn RS, Smith TJ 2003 Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 24:802-835 (Pubitemid 38067700)
2. Rapoport B, McLachlan SM 2001 Thyroid autoimmunity. J Clin Invest 108:1253-1259 (Pubitemid 33107748)
3. + regulatory T cells in a mouse model. Endocrinology 147:2417-2422
4. Díez JJ, Hernanz A, Medina S, Bayón C, Iglesias P 2002 Serum concentrations of tumor necrosis factor-alpha (TNF-α) and soluble TNF-receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol (Oxf) 57:515-521 (Pubitemid 35216303)
5. +regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. J Immunol 186:4734-4743
6. Kuang M, Wang S, Wu M, Ning G, Yao Z, Li L 2010 Expression of IFNα-inducible genes and modulation of HLA-DR and thyroid stimulating hormone receptors in Graves' disease. Mol Cell Endocrinol 319:23-29
7. Ajjan RA, Watson PF, Weetman AP 1996 Cytokines and thyroid function. Adv Neuroimmunol 6:359-386 (Pubitemid 27249231)
8. Gianoukakis AG, Khadavi N, Smith TJ 2008 Cytokines, Graves'disease, and thyroid-associated ophthalmopathy. Thyroid 18:953-958
9. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H 2000 Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:860-864 (Pubitemid 30084330)
10. Morimoto J, Kon S, Matsui Y, Uede T 2010 Osteopontin; as a target molecule for the treatment of inflammatory diseases. Curr Drug Targets 11:494-505
11. Xu G, Nie H, Li N, Zheng W, Zhang D, Feng G, Ni L, Xu R, Hong J, Zhang JZ 2005 Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 115:1060-1067 (Pubitemid 40489411)
12. + T cell-mediated graft-versus-host disease. Blood 117:1723-1733
13. Gravallese EM 2003 Osteopontin: a bridge between bone and the immune system. J Clin Invest 112:147-149 (Pubitemid 38056349)
14. Weber GF, Ashkar S, Glimcher MJ, Cantor H 1996 Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271:509-512 (Pubitemid 26044470)
15. Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB2009 Age- and gender-specific modulation of serum osteopontin and interferon-a by osteopontin genotype in systemic lupus erythematosus. Genes Immun 10:487-494